Jorge Alvar

Active 1988–2025

71
Papers
18,180
Citations
57
h-index
71
i10-index

Citations

Citations per year for Jorge Alvar1989: 3 citations1990: 3 citations1994: 3 citations1995: 7 citations1996: 3 citations1997: 8 citations1998: 8 citations1999: 27 citations2000: 24 citations2001: 45 citations2002: 58 citations2003: 60 citations2004: 52 citations2005: 63 citations2006: 91 citations2007: 85 citations2008: 132 citations2009: 110 citations2010: 119 citations2011: 145 citations2012: 121 citations2013: 140 citations2014: 225 citations2015: 119 citations2016: 151 citations2017: 112 citations2018: 109 citations2019: 553 citations2020: 545 citations2021: 488 citations2022: 259 citations2023: 163 citations2024: 274 citations2025: 102 citations2026: 2 citations1991–1993: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 561 citing papers, 11.4% of this breakdownBrazil: 559 citing papers, 11.3% of this breakdownUnited Kingdom: 380 citing papers, 7.7% of this breakdownIndia: 312 citing papers, 6.3% of this breakdownSpain: 310 citing papers, 6.3% of this breakdownSwitzerland: 222 citing papers, 4.5% of this breakdownFrance: 193 citing papers, 3.9% of this breakdownItaly: 164 citing papers, 3.3% of this breakdownIran: 160 citing papers, 3.3% of this breakdownBelgium: 136 citing papers, 2.8% of this breakdownGermany: 123 citing papers, 2.5% of this breakdownCanada: 108 citing papers, 2.2% of this breakdown
0%11.4%Other 34.5%

Fields

  • Medicine86.5%
  • Immunology and Microbiology6.7%
  • Biochemistry, Genetics and Molecular Biology2.7%
  • Agricultural and Biological Sciences0.9%
  • Environmental Science0.5%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • Other2.2%

Topics

  • Research on Leishmaniasis Studies30.8%
  • Trypanosoma species research and implications19.3%
  • Parasites and Host Interactions7.2%
  • Synthesis and Biological Evaluation2.1%
  • Toxoplasma gondii Research Studies1.7%
  • Leptospirosis research and findings1.4%
  • Other37.5%

Coauthors

All papers

Open in search
  1. Leishmaniasis Worldwide and Global Estimates of Its Incidence

    Authors: , , , , , , , , - PLoS ONE 2012 cited by 5,178

  2. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

    Authors: , , , , , , , - Nature Reviews Microbiology 2007 cited by 1,482

  3. Quantifying the Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand Flies

    Authors: , , , , , , , , , , , - Clinical Infectious Diseases 2018 cited by 139

  4. Leishmaniasis and poverty

    Authors: , , - Trends in Parasitology 2006 cited by 834

  5. Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2022 cited by 71

  6. Towards the elimination of visceral leishmaniasis as a public health problem in east Africa: reflections on an enhanced control strategy and a call for action

    Authors: , , - The Lancet Global Health 2021 cited by 98

  7. Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study

    Authors: , , , , , , , , , , , , , , , , , , , , - PLoS neglected tropical diseases 2023 cited by 34

  8. Reviews Of Anti‐infective Agents: Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis

    Authors: , , , , , , , , , , , , , , - Clinical Infectious Diseases 2006 cited by 340

  9. Eliminating visceral leishmaniasis in South Asia: the road ahead

    Authors: , , , , , - BMJ 2019 cited by 145

  10. Canine leishmaniasis: epidemiological risk and the experimental model

    Authors: , - Trends in Parasitology 2002 cited by 501

  11. Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives

    Authors: , , , , , , , , , , , , , , , , - Clinical Microbiology Reviews 2018 cited by 216

  12. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia

    Authors: , , , , , , , , , , , , , , , , , , , , , - PLoS neglected tropical diseases 2019 cited by 85

  13. Combination therapy for visceral leishmaniasis

    Authors: , , , , , - The Lancet Infectious Diseases 2010 cited by 333

  14. Cutaneous leishmaniasis and co-morbid major depressive disorder: A systematic review with burden estimates

    Authors: , , , , , , , , , , , , , - PLoS neglected tropical diseases 2019 cited by 108

  15. Of Cattle, Sand Flies and Men: A Systematic Review of Risk Factor Analyses for South Asian Visceral Leishmaniasis and Implications for Elimination

    Authors: , , - PLoS neglected tropical diseases 2010 cited by 159

  16. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.

    Authors: , , , , - PLoS neglected tropical diseases 2017 cited by 144

  17. Case study for a vaccine against leishmaniasis

    Authors: , , , , , - Vaccine 2013 cited by 121

  18. Interventions for American cutaneous and mucocutaneous leishmaniasis

    Authors: , , , , , - Cochrane Database of Systematic Reviews 2009 cited by 206

  19. Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia

    Authors: , , , , , , , , , , , , , , , , , - PLoS neglected tropical diseases 2019 cited by 43

  20. Canine Leishmaniasis

    Authors: , , , , - Advances in Parasitology/Advances in parasitology 2004 cited by 430

  21. A nested polymerase chain reaction (Ln-PCR) for diagnosing and monitoring Leishmania infantum infection in patients co-infected with human immunodeficiency virus

    Authors: , , , , , , , , , - Transactions of the Royal Society of Tropical Medicine and Hygiene 2002 cited by 210

  22. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh

    Authors: , , , , , , , , , , , , , - PLoS neglected tropical diseases 2017 cited by 75

  23. Role of asymptomatic and symptomatic humans as reservoirs of visceral leishmaniasis in a Mediterranean context

    Authors: , , , , , , , , - PLoS neglected tropical diseases 2020 cited by 60

  24. Implications of asymptomatic infection for the natural history of selected parasitic tropical diseases

    Authors: , , , , , , , , , , , , , , , - Seminars in Immunopathology 2020 cited by 52